The human papillomavirus (HPV) therapeutics market will register a CAGR of nearly 9% by 2023

Tuesday, February 12, 2019 Sexual Health News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 11, 2019 /PRNewswire/ -- About this marketTechnological advances in diagnostics to drive market growth.

The diagnostic methods that are currently available in the market include Pap test, colposcopy, and HPV DNA test. Pap test is a screening procedure for cervical cancer, in which the presence of precancerous or cancerous cells is identified on the cervix.
Colposcopy is a more advanced technique like a Pap test, which allows the examiner to take abnormal cell tissues from the cervix. Technavio's analysts have predicted that the human papillomavirus (HPV) therapeutics market will register a CAGR of nearly 9% by 2023.Read the full report: https://www.reportlinker.com/p05734222 Market OverviewAdvent of vaccinesThe global HPV therapeutics market witnessed strong advances in terms of prevention of diseases caused by HPV. This is primarily due to the increasing research on developing highly advanced vaccines with a longer half-life. Vaccines were proved to have strong efficacy toward the prevention of various disease-causing viruses and highly effective toward the prevention of various indications caused by HPV.Multiple-dose schedules of vaccinesDespite the availability of vaccines for the prevention of indications caused by HPV, the market faces a challenge from their recurring doses. As the vaccines that are currently approved for HPV are developed for administering through invasive methods such as subcutaneous route, the need for multiple doses affects the patient adherence toward the completion of the dose cycle.For the detailed list of factors that will drive and challenge the growth of the human papillomavirus (HPV) therapeutics market during the 2019-2023, view our report.Competitive LandscapeThe market appears to be fragmented and with the presence of several companies including ALLERGAN and Bausch Health the competitive environment is quite intense. Factors such as the advent of vaccines and the technological advances in diagnostics, will provide considerable growth opportunities to human papillomavirus (HPV) manufactures. ALLERGAN, Bausch Health, GlaxoSmithKline, Lee's Pharmaceutical Holdings, and Merck Sharp & Dohme are some of the major companies covered in this report.Read the full report: https://www.reportlinker.com/p05734222 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-human-papillomavirus-hpv-therapeutics-market-will-register-a-cagr-of-nearly-9-by-2023-300793250.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store